Mosges R - Search Results

1

Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis.

Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, Muraro A, Roberts G, Akdis CA, Bonini M, Cavkaytar O, Flood B, Gajdanowicz P, Izuhara K, Kalayci Ö, Mosges R, Palomares O, Pfaar O, Smolinska S, Sokolowska M, Asaria M, Netuveli G, Zaman H, Akhlaq A, Sheikh A. Dhami S, et al. Among authors: mosges r. Allergy. 2017 Dec;72(12):1825-1848. doi: 10.1111/all.13208. Epub 2017 Jul 6. Allergy. 2017. PMID: 28543086 Free article. Review.

2

Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment.

Spaeth J, Klimek L, Mösges R. Spaeth J, et al. Among authors: mosges r. Allergy. 1996 Dec;51(12):893-906. doi: 10.1111/j.1398-9995.1996.tb04490.x. Allergy. 1996. PMID: 9020417 Clinical Trial.

3

Generic or disease-specific quality of life scales to characterize health status in allergic rhinitis?

Kremer B, Klimek L, Bullinger M, Mösges R. Kremer B, et al. Among authors: mosges r. Allergy. 2001 Oct;56(10):957-63. doi: 10.1034/j.1398-9995.2001.00919.x. Allergy. 2001. PMID: 11576074

4

Comparison of the biological activity of the most common sublingual allergen solutions made by two European manufacturers.

Mösges R, Pasch N, Schlierenkämper U, Lehmacher W. Mösges R, et al. Int Arch Allergy Immunol. 2006;139(4):325-9. doi: 10.1159/000091604. Epub 2006 Feb 27. Int Arch Allergy Immunol. 2006. PMID: 16508333 Clinical Trial.

5

Today's allergic rhinitis patients are different: new factors that may play a role.

Mösges R, Klimek L. Mösges R, et al. Allergy. 2007 Sep;62(9):969-75. doi: 10.1111/j.1398-9995.2007.01440.x. Allergy. 2007. PMID: 17686101 Review.

6

Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens.

Pfaar O, Klimek L, Fischer I, Sieber J, Amoroso S, Moreno Aguilar C, Shah K, Mösges R. Pfaar O, et al. Among authors: mosges r. Int Arch Allergy Immunol. 2009;150(1):102-8. doi: 10.1159/000210436. Epub 2009 Apr 2. Int Arch Allergy Immunol. 2009. PMID: 19339808 Clinical Trial.

7

[Cluster immunotherapy of persistent allergic rhinoconjunctivitis. Safety aspects of induction therapy with mite depot allergen preparations].

Pfaar O, Mösges R, Hörmann K, Klimek L. Pfaar O, et al. Among authors: mosges r. HNO. 2009 Nov;57(11):1099-105. doi: 10.1007/s00106-009-1946-8. HNO. 2009. PMID: 19585090 German.

8

Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis.

Pfaar O, Mösges R, Hörmann K, Klimek L. Pfaar O, et al. Among authors: mosges r. Eur Arch Otorhinolaryngol. 2010 Feb;267(2):245-50. doi: 10.1007/s00405-009-1077-6. Eur Arch Otorhinolaryngol. 2010. PMID: 19756683

9

Towards evidence-based medicine in specific grass pollen immunotherapy.

Calderon M, Mösges R, Hellmich M, Demoly P. Calderon M, et al. Among authors: mosges r. Allergy. 2010 Apr;65(4):420-34. doi: 10.1111/j.1398-9995.2009.02292.x. Epub 2009 Dec 21. Allergy. 2010. PMID: 20028374 Review.

10

Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.

Mösges R, Ritter B, Kayoko G, Allekotte S. Mösges R, et al. Acta Dermatovenerol Alp Pannonica Adriat. 2010 Oct;19(3):3-10. Acta Dermatovenerol Alp Pannonica Adriat. 2010. PMID: 20976414 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

309 results

Search Page

Filters